Relatlimab Biosimilar - Ultra Low Endotoxin

Human

LAG3

>1mg/ml

Human IgG4 S228P Kappa

Anti-Mouse LAG-3 (C9B7W) In Vivo Antibody - Low Endotoxin (ICH1078), TSR-033 Biosimilar - Research Grade (ICH5067), Ieramilimab Biosimilar - Research Grade (ICH5098), Miptenalimab Biosimilar - Research Grade (ICH5259), Encelimab Biosimilar - Research Grade (ICH5524), Favezelimab Biosimilar - Research Grade (ICH5545), Fianlimab Biosimilar - Research Grade (ICH5548), Negalstobart Biosimilar - Research Grade (ICH5704), Tuparstobart Biosimilar - Research Grade (ICH5948)

https://www.imgt.org/mAb-DB/

ICH3002

P18627

Blue ice

This is an unconjugated, non-therapeutic recombinant analog of the anti-LAG-3 antibody relatlimab, engineered as a human IgG4 (S228P) kappa molecule directed against human LAG3 (Lymphocyte-activation gene 3, UniProt P18627). It is supplied for research use only and is not the clinical drug, nor is it intended for human or veterinary use. Built around the LAG3 target, it is useful as a well-characterized binding and blocking reagent for immuno-oncology and checkpoint-biology workflows: as a positive control or reference antibody in target-engagement and epitope-competition assays, for probing LAG3 expression and downregulation on activated T cells, in receptor-blockade and functional T-cell restoration experiments in vitro, and as a benchmark tool alongside anti-PD-1 reagents for combination studies. The S228P hinge stabilization reduces Fab-arm exchange, giving consistent bivalent behavior. Material is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities to support assay development, screening, and preclinical modeling where lot-to-lot consistency and scale matter. LAG3 (CD223) is an inhibitory immune checkpoint receptor expressed on activated CD4+ and CD8+ T cells, regulatory T cells, NK cells, B cells, and plasmacytoid dendritic cells. Structurally related to CD4, it contains four extracellular immunoglobulin-like domains and binds MHC class II with higher affinity than CD4. Additional reported ligands include fibrinogen-like protein 1 (FGL1), galectin-3, and LSECtin. Engagement transmits inhibitory signals via its cytoplasmic domain, notably a conserved KIEELE motif, dampening T-cell proliferation, cytokine production, and effector function while contributing to regulatory T-cell suppressive activity. LAG3 is upregulated on chronically stimulated, exhausted T cells within tumors and chronic infection, often co-expressed with PD-1, making it a prominent target for checkpoint blockade. Blocking LAG3 can restore antitumor T-cell responses, and dual LAG3/PD-1 inhibition shows cooperative reinvigoration of exhausted T cells.

Lymphocyte activation gene 3 protein, FDC

Detects human LAG3

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Why choose the ultra-low-endotoxin Relatlimab biosimilar?

A: The ultra-low-endotoxin format minimises endotoxin-driven background, making it well suited to sensitive in vivo and functional studies.

Q: Can I order the Relatlimab biosimilar in bulk?

A: Yes — it is manufactured in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: What does the Relatlimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Relatlimab that binds human LAG3 for research use only (RUO).